BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22753586)

  • 1. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
    Bae J; Smith R; Daley J; Mimura N; Tai YT; Anderson KC; Munshi NC
    Clin Cancer Res; 2012 Sep; 18(17):4850-60. PubMed ID: 22753586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.
    Bae J; Prabhala R; Voskertchian A; Brown A; Maguire C; Richardson P; Dranoff G; Anderson KC; Munshi NC
    Leukemia; 2015 Jan; 29(1):218-29. PubMed ID: 24935722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.
    Bae J; Carrasco R; Lee AH; Prabhala R; Tai YT; Anderson KC; Munshi NC
    Leukemia; 2011 Oct; 25(10):1610-9. PubMed ID: 21660045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
    Bae J; Tai YT; Anderson KC; Munshi NC
    Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
    Bae J; Song W; Smith R; Daley J; Tai YT; Anderson KC; Munshi NC
    Br J Haematol; 2012 Jun; 157(6):687-701. PubMed ID: 22533610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
    Bae J; Hideshima T; Zhang GL; Zhou J; Keskin DB; Munshi NC; Anderson KC
    Leukemia; 2018 Mar; 32(3):752-764. PubMed ID: 29089645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
    Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
    J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
    Jalili A; Ozaki S; Hara T; Shibata H; Hashimoto T; Abe M; Nishioka Y; Matsumoto T
    Blood; 2005 Nov; 106(10):3538-45. PubMed ID: 16037388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
    Front Immunol; 2019; 10():1792. PubMed ID: 31428094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
    Bae J; Hideshima T; Tai YT; Song Y; Richardson P; Raje N; Munshi NC; Anderson KC
    Leukemia; 2018 Sep; 32(9):1932-1947. PubMed ID: 29487385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.
    Kang YJ; Zeng W; Song W; Reinhold B; Choi J; Brusic V; Yamashita T; Munshi A; Li C; Minvielle S; Anderson KC; Munshi N; Reinherz EL; Sasada T
    Br J Haematol; 2013 Nov; 163(3):343-51. PubMed ID: 24032635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
    Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
    Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
    Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
    Qian J; Xie J; Hong S; Yang J; Zhang L; Han X; Wang M; Zhan F; Shaughnessy JD; Epstein J; Kwak LW; Yi Q
    Blood; 2007 Sep; 110(5):1587-94. PubMed ID: 17515399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.
    Li R; Qian J; Zhang W; Fu W; Du J; Jiang H; Zhang H; Zhang C; Xi H; Yi Q; Hou J
    Br J Haematol; 2014 Sep; 166(5):690-701. PubMed ID: 24824351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.